[go: up one dir, main page]

NO20016116L - Substituerte heterocykelfuserte <gamma>-karboliner - Google Patents

Substituerte heterocykelfuserte <gamma>-karboliner

Info

Publication number
NO20016116L
NO20016116L NO20016116A NO20016116A NO20016116L NO 20016116 L NO20016116 L NO 20016116L NO 20016116 A NO20016116 A NO 20016116A NO 20016116 A NO20016116 A NO 20016116A NO 20016116 L NO20016116 L NO 20016116L
Authority
NO
Norway
Prior art keywords
carbolines
gamma
fused
substituted heterocycle
heterocycle
Prior art date
Application number
NO20016116A
Other languages
English (en)
Norwegian (no)
Other versions
NO20016116D0 (no
Inventor
Albert J Robichaud
Taekyu Lee
Wei Deng
Ian S Mitchell
Michael Guang Yang
Simon Haydar
Wenting Chen
Christopher D Mcclung
Emilie J B Calvello
David M Zawrotny
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of NO20016116D0 publication Critical patent/NO20016116D0/no
Publication of NO20016116L publication Critical patent/NO20016116L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20016116A 1999-06-15 2001-12-14 Substituerte heterocykelfuserte <gamma>-karboliner NO20016116L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13932199P 1999-06-15 1999-06-15
PCT/US2000/016498 WO2000077002A1 (fr) 1999-06-15 2000-06-15 Gamma-carbolines fusionnees a heterocycle substitue

Publications (2)

Publication Number Publication Date
NO20016116D0 NO20016116D0 (no) 2001-12-14
NO20016116L true NO20016116L (no) 2002-02-11

Family

ID=22486095

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20016116A NO20016116L (no) 1999-06-15 2001-12-14 Substituerte heterocykelfuserte <gamma>-karboliner
NO20016115A NO20016115L (no) 1999-06-15 2001-12-14 Substituerte heterosykelkondenserte gamma-karbolin
NO20016128A NO20016128L (no) 1999-06-15 2001-12-14 Substituerte, heterocykliske, fuserte <gamma>-karboliner

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20016115A NO20016115L (no) 1999-06-15 2001-12-14 Substituerte heterosykelkondenserte gamma-karbolin
NO20016128A NO20016128L (no) 1999-06-15 2001-12-14 Substituerte, heterocykliske, fuserte <gamma>-karboliner

Country Status (19)

Country Link
US (7) US6552017B1 (fr)
EP (3) EP1189904B1 (fr)
JP (3) JP4863591B2 (fr)
CN (3) CN1370169A (fr)
AR (3) AR024379A1 (fr)
AT (3) ATE277928T1 (fr)
AU (3) AU5615900A (fr)
BR (3) BR0012086A (fr)
CA (3) CA2373920A1 (fr)
DE (3) DE60014083T2 (fr)
ES (3) ES2223537T3 (fr)
HK (3) HK1042480A1 (fr)
IL (3) IL147108A0 (fr)
MX (3) MXPA01012914A (fr)
NO (3) NO20016116L (fr)
NZ (1) NZ516031A (fr)
TR (1) TR200103658T2 (fr)
WO (3) WO2000077002A1 (fr)
ZA (1) ZA200109735B (fr)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
DE60014083T2 (de) * 1999-06-15 2006-03-02 Bristol-Myers Squibb Pharma Co., Wilmington Substituierte heterocyclylkondensierte gamma carboline
WO2002024700A2 (fr) 2000-09-20 2002-03-28 Pharmacia & Upjohn Company Derives d'azepino[4,5b]indoline substitues
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
DK1337518T3 (da) 2000-11-20 2009-10-19 Biovitrum Ab Publ Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
BR0116429A (pt) * 2000-12-20 2006-05-09 Bristol Myers Squibb Co piridoindóis substituìdos como agonistas e antagonistas da serotonina
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
JP2004534781A (ja) * 2001-06-01 2004-11-18 アルコン，インコーポレイテッド 新規なアリールアミノプロパン類似体および緑内障治療へのこれらの使用
CA2447156A1 (fr) * 2001-06-01 2002-12-12 Alcon, Inc. Indazoles et indoles nouveaux fusionnes et leur utilisation dans le traitement de glaucomes
DK1392292T3 (da) * 2001-06-01 2006-05-29 Alcon Inc Pyranoindazoler og deres anvendelse til behandling af glaukom
US20030060462A1 (en) * 2001-08-06 2003-03-27 Hoffman Robert L. Therapeutic compounds
MXPA04001202A (es) 2001-08-06 2005-02-17 Pharmacia & Upjhon Company Ligandos tetraciclicos terapeuticamente utiles.
WO2003024976A2 (fr) * 2001-09-21 2003-03-27 Pharmacia & Upjohn Company Composes therapeutiques de ligand du recepteur 5-ht
WO2003033497A1 (fr) * 2001-10-18 2003-04-24 Pharmacia & Upjohn Company Tetracycliques azaindoles et indolines modulant l'activite de 5-ht
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
BR0311970A (pt) 2002-06-19 2005-03-29 Biovitrum Ab Novos compostos, seu uso e preparação
US6958420B2 (en) * 2002-07-19 2005-10-25 Board Of Trustees Of Michigan State University Synthesis of aminoarylboronic esters and substituted anilines from arenes via catalytic C-H activation/borylation/amination and uses thereof
MXPA05002259A (es) * 2002-08-30 2005-07-05 Alcon Inc Compuestos de 5-croman-5-il-etilamina sustituidos y uso para el tratamiento de glaucoma.
JP2006511556A (ja) 2002-12-13 2006-04-06 アルコン，インコーポレイテッド 新規のベンゾピラン類似体及び緑内障の治療のためのそれらの使用
PL377426A1 (pl) 2002-12-19 2006-02-06 Bristol-Myers Squibb Company Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7728155B2 (en) 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005053688A1 (fr) 2003-11-26 2005-06-16 Alcon, Inc. Furo[2,3-g] indazoles substitues destines au traitement du glaucome
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
WO2005058911A2 (fr) 2003-12-15 2005-06-30 Alcon, Inc. [1,4]oxazino[2,3-g]indazoles substitues pour traiter le glaucome
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
PL1737461T3 (pl) 2004-03-15 2013-05-31 Ptc Therapeutics Inc Pochodne karbolinowe użyteczne w hamowaniu angiogenezy
MXPA06014565A (es) 2004-06-18 2007-03-23 Wyeth Corp Procesos para preparar 6-alquil-5-arilsulfonil-dihidrofenantridinas.
EP2400300A1 (fr) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Procédé de sélection d'agents préventifs/remèdes pour l'incontinence de stress
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
WO2006062839A1 (fr) 2004-12-08 2006-06-15 Alcon, Inc. Utilisation de dioxindoindazoles et de dioxoloindazoles pour traiter le glaucome
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
KR101503681B1 (ko) * 2006-01-19 2015-03-19 아더시스 인코포레이티드 세로토닌 5-ｈｔ2ｃ 수용체 리간드로서의 티오페닐 및 피롤릴 아제핀 및 이의 용도
WO2007132841A1 (fr) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné et utilisation
CA2666193A1 (fr) 2006-08-08 2008-02-14 Sanofi-Aventis Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituee, son procede de fabrication, medicament contenant ce compose et son utilisation
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
EP2240481A1 (fr) * 2008-01-11 2010-10-20 Albany Molecular Research, Inc. Pyridoindoles (1-azinone)-substitués en tant qu'antagonistes mch
JP5611846B2 (ja) 2008-03-12 2014-10-22 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 置換ヘテロ環縮合ガンマ−カルボリン類固体
MX377802B (es) 2008-05-27 2025-03-11 Intra Cellular Therapies Inc Metodos y composiciones para trastornos del sueño y otros trastornos.
AU2015218433B2 (en) * 2008-05-27 2017-07-27 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
CA2930674A1 (fr) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP2310372B1 (fr) 2008-07-09 2012-05-23 Sanofi Composés hétérocycliques, leur procédé de préparation, médicaments les contenant et leur utilisation
US9107696B2 (en) * 2008-08-06 2015-08-18 Emory University Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus
EP2344505A2 (fr) * 2008-09-29 2011-07-20 Abbott Laboratories Dérivés d'indole et d'indoline et procédés d'utilisation de ceux-ci
US9625475B2 (en) * 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
WO2011003021A1 (fr) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 azabicycloalcane-indoles et azabicycloalcane-pyrrolo-pyridines substitués par azinone, leurs procédés de fabrication et leur utilisation
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003005A1 (fr) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 d’azépino[b]indole et pyrido-pyrrolo-azépine azinone-substitué, procédés de préparation, et utilisation de ceux-ci
WO2011003012A1 (fr) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 azapolycycles substitués par azinone, leurs procédés de fabrication et leur utilisation
BR112012000788A2 (pt) 2009-07-14 2016-02-23 Albany Molecular Res Inc moduladores do receptor 5-ht3, métodos para preparar e uso dos mesmos
WO2011023754A1 (fr) 2009-08-26 2011-03-03 Sanofi-Aventis Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, substances pharmaceutiques comprenant ces composés et leur utilisation
US8575186B2 (en) 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
WO2011071136A1 (fr) 2009-12-11 2011-06-16 アステラス製薬株式会社 Agent thérapeutique pour la fibromyalgie
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103460A1 (fr) * 2010-02-18 2011-08-25 Medivation Technologies, Inc. Dérivés de pyrido[4,3-b]indole et pyrido[3,4-b]indole tétracyclique condensés et procédés d'utilisation
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
RU2591194C2 (ru) * 2010-04-22 2016-07-10 Интра-Селлулар Терапиз, Инк. Органические соединения
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012088124A2 (fr) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Antagonistes de la mch-1 à base de tétrahydro-azacarboline, leurs procédés de fabrication et leurs utilisations
WO2012088038A2 (fr) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Antagonistes de mch-1 consistant en tétrahydro-carbolines substituées par pipérazinone, leurs procédés de fabrication et utilisations
EP2668191A4 (fr) 2011-01-19 2014-08-20 Albany Molecular Res Inc Benzofuro[3,2-c]pyridines et analogues associés en tant que modulateurs du sous-type 6 de la sérotonine (5-ht6) pour traitement de l'obésité, du syndrome métabolique, de la cognition et de la schizophrénie
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
CA2828346C (fr) 2011-03-01 2021-01-26 Synergy Pharmaceuticals Inc. Procede de preparation d'agonistes du guanylate cyclase c
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120057A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013155506A1 (fr) * 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Nouvelles compositions et nouveaux procédés
EP3610890A1 (fr) 2012-11-14 2020-02-19 The Johns Hopkins University Procédés et compositions de traitement de la schizophrénie
EP2981266B1 (fr) * 2013-03-04 2018-01-03 Daya CNS LLC Dérivés de pyridoindolobenz[b,d]azépines pentacycliques et leurs utilisations
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
DK2968320T3 (da) 2013-03-15 2021-02-01 Intra Cellular Therapies Inc Organiske forbindelser
EP4424697A3 (fr) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Agonistes ultra-purs de guanylate cyclase c, leur procédé de fabrication et d'utilisation
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation
AU2014360452C1 (en) 2013-12-03 2019-05-16 Intra-Cellular Therapies, Inc. Novel methods
JP2017509677A (ja) 2014-04-04 2017-04-06 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
MX365969B (es) 2014-04-04 2019-06-21 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
US10646648B2 (en) 2015-04-01 2020-05-12 Becton, Dickinson And Company IV flow management systems and methods
EP3286172B1 (fr) 2015-04-23 2019-06-12 Constellation Pharmaceuticals, Inc. Inhibiteurs de lsd1 et leurs utilisations
ES2863471T3 (es) * 2016-01-26 2021-10-11 Intra Cellular Therapies Inc Compuestos de piridopirroloquinoxalina, sus composiciones y usos
RU2733975C2 (ru) 2016-03-25 2020-10-08 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2017172811A1 (fr) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Nouveaux co-cristaux
EP3436083A4 (fr) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Nouvelles compositions et méthodes
WO2017172784A1 (fr) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Nouveaux sels et cristaux
US12343337B2 (en) 2016-09-29 2025-07-01 The Regents Of The University Of California Compounds for increasing neural plasticity
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
US10517849B2 (en) 2016-10-26 2019-12-31 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and medical uses thereof
WO2018106916A1 (fr) * 2016-12-07 2018-06-14 Concert Pharmaceuticals, Inc. Composés de quinoxaline deutérés
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
KR102398194B1 (ko) 2017-03-24 2022-05-18 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 조성물 및 방법
JP2020513023A (ja) 2017-04-10 2020-04-30 ドクター・レディーズ・ラボラトリーズ・リミテッド ルマテペロンｐ−トシラートの非晶質形態および固体分散体
CN111093664B (zh) * 2017-07-26 2023-06-02 细胞内治疗公司 有机化合物
JP7223742B2 (ja) 2017-07-26 2023-02-16 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
WO2019067591A1 (fr) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. Nouveaux sels et cristaux
EP3717484A4 (fr) * 2017-11-27 2021-08-04 Egis Gyógyszergyár Zrt. Procédé pour la fabrication de lumatépérone et de ses sels
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
MX2020009928A (es) 2018-03-23 2021-01-08 Intra Cellular Therapies Inc Compuestos organicos.
WO2019183546A1 (fr) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Composés organiques
MX2020013116A (es) 2018-06-06 2021-05-12 Intra Cellular Therapies Inc Sales y cristales novedosos.
MX2020013335A (es) 2018-06-08 2021-05-27 Intra Cellular Therapies Inc Metodos novedosos.
KR102778034B1 (ko) * 2018-06-11 2025-03-12 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
AU2019288476A1 (en) 2018-06-21 2021-03-18 Aquestive Therapeutics, Inc. System and method for making personalized individual unit doses containing pharmaceutical actives
CN109100437A (zh) * 2018-07-22 2018-12-28 邯郸学院 仲胺类抗抑郁药物的质谱检测方法
EP3830093A1 (fr) 2018-07-27 2021-06-09 Biotheryx, Inc. Composés bifonctionnels agissant par agonisme sur des cdk
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
JP7457000B2 (ja) 2018-08-31 2024-03-27 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
EP3843738A4 (fr) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. Nouvelles méthodes
CN120789028A (zh) 2018-09-07 2025-10-17 阿奎蒂夫疗法公司 具有精确的活性物溶出谱的口腔膜组合物和剂型
EP3887374A2 (fr) 2018-11-27 2021-10-06 Teva Pharmaceuticals International GmbH Formes à l'état solide de sels de lumatépérone et procédés de préparation de lumatépérone et de ses sels
JP7520012B2 (ja) 2018-12-17 2024-07-22 イントラ－セルラー・セラピーズ・インコーポレイテッド 置換複素環縮合γ－カルボリンの合成
CN113423568A (zh) * 2018-12-17 2021-09-21 细胞内治疗公司 有机化合物
EP3898581B1 (fr) 2018-12-17 2025-08-27 Intra-Cellular Therapies, Inc. Synthèse de gamma-carbolines fusionnées à hétérocycles substitués
WO2020132474A1 (fr) * 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Composé organique
US12331052B2 (en) 2018-12-21 2025-06-17 Intra-Cellular Therapies, Inc. Organic compounds
EP3914235A4 (fr) * 2019-01-23 2022-09-07 Intra-Cellular Therapies, Inc. Procédés de traitement de la dépendance
WO2020176599A1 (fr) 2019-02-27 2020-09-03 The Regents Of The University Of California Azépino-indoles et autres hétérocycles pour traiter des troubles du cerveau
CN113905737A (zh) * 2019-04-04 2022-01-07 细胞内治疗公司 治疗神经性疼痛的方法
US20210000822A1 (en) 2019-07-07 2021-01-07 Intra-Cellular Therapies, Inc. Novel methods
CA3159382A1 (fr) 2019-11-01 2021-05-06 Aquestive Therapeutics, Inc. Compositions de promedicament et procedes de traitement
EP4058029B1 (fr) 2019-11-14 2025-03-26 Aquestive Therapeutics, Inc. Compositions multimodales et méthodes de traitement
JP7261942B2 (ja) * 2019-12-11 2023-04-20 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP7727634B2 (ja) 2019-12-19 2025-08-21 イントラ－セルラー・セラピーズ・インコーポレイテッド 統合失調症処置方法
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN116568302B (zh) * 2020-10-09 2025-04-18 上海枢境生物科技有限公司 杂环取代的稠合γ-咔啉类衍生物、其制备方法、中间体及应用
CN112062767B (zh) * 2020-10-20 2022-03-11 杭州科巢生物科技有限公司 一种卢美哌隆的制备方法及其中间体
CN116940351A (zh) 2021-01-15 2023-10-24 阿奎斯蒂弗医疗股份有限公司 前药组合物和治疗方法
CA3210706A1 (fr) 2021-03-09 2022-09-15 Alexander Mark Schobel Formes pharmaceutiques ayant des profils biocomparables equivalents
CA3239565A1 (fr) 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Psychoplastogenes substitues par phenoxy et benzyloxy et leurs utilisations
KR20240146002A (ko) * 2022-01-14 2024-10-07 상하이테크 유니버시티 융합 고리 피페리딘계 화합물, 이의 제조 방법, 및 이의 용도
CN114456149A (zh) * 2022-02-24 2022-05-10 中国科学技术大学 一种多巴胺drd2受体拮抗剂及其用途
US20250101029A1 (en) * 2022-03-14 2025-03-27 Intra-Cellular Therapies, Inc. Organic compounds
AU2023236707A1 (en) * 2022-03-14 2024-09-12 Intra-Cellular Therapies, Inc. Organic compounds
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
WO2023225620A1 (fr) 2022-05-18 2023-11-23 Intra-Cellular Therapies, Inc. Nouveaux procédés
CN120417904A (zh) 2022-12-30 2025-08-01 细胞内治疗公司 作用于血清素5-HT2A受体的杂环稠合γ-咔啉
WO2024173901A1 (fr) 2023-02-17 2024-08-22 Intra-Cellular Therapies, Inc. Lumatépérone et ses dérivés pour moduler le système nerveux
WO2025111568A1 (fr) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumatépérone et analogues, modulateurs du récepteur 5-ht2a ou 5-ht2a/d2, destinés à être utilisés dans le traitement de troubles psychiatriques provoqués par l'encéphalite virale, bactérienne ou auto-immune, et de symptômes psychiatriques de ceux-ci
CN119930620A (zh) * 2024-02-05 2025-05-06 和径医药科技（上海）有限公司 四并环类化合物、其制备方法、药物组合物及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299078A (en) * 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3892746A (en) 1969-06-09 1975-07-01 American Home Prod Pyrrolo{8 1,2,3-de{9 quinoxalin-2(3H)-ones and related compounds
US3813392A (en) * 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US3891643A (en) 1972-05-15 1975-06-24 American Home Prod Pyrrolo{8 1,2,3-de{9 quinoxalin-2-(3H)-ones and related compounds
US4013652A (en) 1972-06-19 1977-03-22 Endo Laboratories, Inc. Pyridopyrrolobenzoxazine
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
JPS4949999A (fr) * 1973-06-19 1974-05-15
FR2213283A1 (en) 1973-11-15 1974-08-02 Inst Im Ordzhonikidze Pyrazino(1,2,3-ab)beta carbolines and homologues - antidepressants not acting by MAO inhibition
JPS569510B2 (fr) * 1973-11-17 1981-03-02
US4088647A (en) 1976-02-04 1978-05-09 Glushkov Robert Georgievich Pyrazino (1,2,3-ab)-β-carboline derivatives and salts thereof and method of preparing same
US4219550A (en) * 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
DE3855147D1 (de) * 1987-07-20 1996-05-02 Duphar Int Res 8,9-Anellierte 1,2,3,4-Tetrahydro-beta-carbolin-Derivate
US5328905A (en) * 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
EP0347980A1 (fr) * 1988-06-20 1989-12-27 Duphar International Research B.V B-carbolines, 8,9-cyclisées et B-carbolines, 3,4-dihydro, 8,9 cyclisées
JPH02180885A (ja) * 1988-09-01 1990-07-13 Glaxo Group Ltd ラクタム誘導体
US5223625A (en) 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
EP0377238A1 (fr) * 1988-12-22 1990-07-11 Duphar International Research B.V Indolo(3,2-c)-lactames annelés
CA2011107A1 (fr) 1990-02-28 1991-08-31 David E. Bays Derives de lactam
US5512575A (en) 1991-08-15 1996-04-30 Zeneca Limited Methanoanthraceneyl methyl piperidinyl compounds
WO1995011245A1 (fr) * 1993-10-20 1995-04-27 Tokyo Tanabe Company Limited Derive d'indole
US5654139A (en) 1994-09-21 1997-08-05 The United States Of America As Represented By The Department Of Health And Human Services Allelic variation of the serotonin 5HT2c receptor
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
MXPA00010060A (es) 1998-04-14 2004-04-23 Arena Pharm Inc Receptores de serotonina humana constitutivamente activados, no endogenos y moduladores de molecula pequenos de los mismos.
US6140509A (en) 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
DE60014083T2 (de) * 1999-06-15 2006-03-02 Bristol-Myers Squibb Pharma Co., Wilmington Substituierte heterocyclylkondensierte gamma carboline

Also Published As

Publication number Publication date
IL147108A0 (en) 2002-08-14
EP1189905A1 (fr) 2002-03-27
ES2223537T3 (es) 2005-03-01
WO2000077001A1 (fr) 2000-12-21
AR024378A1 (es) 2002-10-02
BR0012084A (pt) 2002-04-02
ZA200109735B (en) 2004-01-27
CA2374239A1 (fr) 2000-12-21
IL145998A0 (en) 2002-07-25
NO20016116D0 (no) 2001-12-14
EP1192165B1 (fr) 2004-09-22
ATE277055T1 (de) 2004-10-15
DE60014370T2 (de) 2006-02-09
ATE277928T1 (de) 2004-10-15
AR024377A1 (es) 2002-10-02
ES2228549T3 (es) 2005-04-16
WO2000077010A2 (fr) 2000-12-21
JP4916633B2 (ja) 2012-04-18
HK1043112A1 (zh) 2002-09-06
US20040034015A1 (en) 2004-02-19
ATE277048T1 (de) 2004-10-15
HK1042480A1 (zh) 2002-08-16
DE60014079D1 (de) 2004-10-28
US20040127482A1 (en) 2004-07-01
DE60014370D1 (de) 2004-11-04
BR0012086A (pt) 2002-04-02
US7238690B2 (en) 2007-07-03
NZ516031A (en) 2003-10-31
MXPA01012969A (es) 2003-10-14
DE60014079T2 (de) 2006-03-02
NO20016115D0 (no) 2001-12-14
EP1192165A2 (fr) 2002-04-03
JP2003502336A (ja) 2003-01-21
JP4762465B2 (ja) 2011-08-31
IL147109A0 (en) 2002-08-14
BR0012411A (pt) 2002-04-16
TR200103658T2 (tr) 2002-06-21
ES2223536T3 (es) 2005-03-01
JP2003502330A (ja) 2003-01-21
EP1189904B1 (fr) 2004-09-22
US20040209864A1 (en) 2004-10-21
US20060178362A1 (en) 2006-08-10
AU5615900A (en) 2001-01-02
CN1370169A (zh) 2002-09-18
NO20016115L (no) 2002-02-12
CA2373920A1 (fr) 2000-12-21
EP1189904A1 (fr) 2002-03-27
EP1189905B1 (fr) 2004-09-29
DE60014083D1 (de) 2004-10-28
WO2000077010A3 (fr) 2001-06-28
US7081455B2 (en) 2006-07-25
NO20016128D0 (no) 2001-12-14
AU5737900A (en) 2001-01-02
JP4863591B2 (ja) 2012-01-25
HK1042481A1 (zh) 2002-08-16
USRE39680E1 (en) 2007-06-05
CA2381322A1 (fr) 2000-12-21
AR024379A1 (es) 2002-10-02
JP2003502331A (ja) 2003-01-21
CN1371374A (zh) 2002-09-25
NO20016128L (no) 2002-02-11
MXPA01012914A (es) 2004-04-21
DE60014083T2 (de) 2006-03-02
MXPA01012970A (es) 2003-10-14
US6548493B1 (en) 2003-04-15
AU5738000A (en) 2001-01-02
US6552017B1 (en) 2003-04-22
CN1370176A (zh) 2002-09-18
WO2000077002A1 (fr) 2000-12-21

Similar Documents

Publication Publication Date Title
NO20016116L (no) Substituerte heterocykelfuserte &lt;gamma&gt;-karboliner
PT1224180E (pt) Azois substituidos
NO20025142D0 (no) PPAR-&lt;gamma&gt;-modulatorer
DE60020617D1 (de) Zementierkopf
NO20016334D0 (no) Boresystem
DZ3377A1 (fr) Azaindoles
DE50014679D1 (de) Substituierte indol-mannichbasen
ATE305470T1 (de) Naphthyridinverbindungen
DE60030631D1 (de) Vermessungssystem
ATE338021T1 (de) Substituierte 2-dialkylaminoalkylbiphenyl- derivate
NO20013997D0 (no) Reseptoranalyse
DE60024400D1 (de) Empfangsgerät
DE50011953D1 (de) Bohrwerkzeug
DE50004713D1 (de) Bohrgerät
DE50011611D1 (de) Bohrwerkzeug
DE60035826D1 (de) Entfernungsmesser
DE60017700D1 (de) Bildgebungsverfahren
NO20022927D0 (no) Substituerte pyrrazoler
DE50011494D1 (de) Bohrwerkzeug
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
DE50011100D1 (de) Bohrwerkzeug
DE19945322B8 (de) Spannfutter
DK1200423T3 (da) Substituerede pehnyluraciler
ID30507A (id) Diarilamina tersubstitusi 1-heterosiklus
UA3532S (uk) Лещата

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application